Although it might be premature to characterize the potential $200 million collaboration between Third Rock Ventures-backed Myokardia Inc. and Sanofi SA as a replicate of the pharma's early interest in Genzyme Corp. that led to that blockbuster acquisition, both partners referenced the relationship in describing their deal to discover and develop precision medicines targeting genetic heart disease.